Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Astrocytes, S2 Circuits, and Tactile Categorization
2026-11-19
A mouse study links chemogenetic modulation of secondary somatosensory-cortex astrocytes with improved vibrotactile categorization and coordinated changes in neuronal gain, adaptation, and sensory signal-to-noise. The findings support a circuit- and task-specific role for astrocytes while leaving the physiological generality of the manipulation unresolved.
How BR Signaling Is Rewired in the Anther
2026-11-19
A recent Arabidopsis study places BSK kinases, BIN2, and BZR transcription factors in a repurposed pathway downstream of EMS1. The comparison of higher-order mutants, developmental phenotypes, protein interactions, and CYCB1;1 measurements supports a signaling architecture for anther patterning, while leaving important questions about spatial specificity and phosphatase action unresolved.
How MRS 2578 Reveals P2Y6 Signaling
2026-11-18
MRS 2578 is described as an insurmountable antagonist of the P2Y6 nucleotide receptor. Its reported effects connect receptor-level inhibition with reduced inositol-phosphate signaling and loss of UDP-associated cellular protection, while also illustrating why functional potency values and selectivity claims must remain tied to their experimental models.
What EP4 Blockade Reveals About Disease Biology
2026-11-18
ONO-AE3-208 is documented as an EP4 antagonist whose reported effects connect prostaglandin signaling with cancer-cell motility, invasion, metastasis, and vascular-wall remodeling. The findings support a preclinical mechanism hypothesis, but each assay measures a different biological level and does not by itself establish clinical efficacy.
How EP4 Blockade Changes PGE2 Signaling
2026-11-17
CJ-42794 is documented as a selective EP4 antagonist whose receptor binding, cellular signaling, inflammatory readout, and tissue-repair effects illustrate how one prostaglandin pathway can produce different outcomes across biological levels.
How EP4 Antagonism Changes PGE2 Signaling
2026-11-17
CJ-42794 is described as a selective EP4 antagonist whose reported effects connect receptor binding with cAMP signaling, inflammatory cytokine output, and gastric repair. The key interpretive question is how strongly these measurements support EP4-specific biological conclusions.
Co-registering Cardiac Structure and Electrophysiology
2026-11-16
A proof-of-concept study combined panoramic hyperspectral imaging with optical mapping in infarcted rat hearts, linking epicardial tissue composition to local electrical activity through a shared three-dimensional surface representation.
What EP4 Blockade Reveals About Inflammation
2026-11-16
L-161,982 provides a conceptual link between EP4 signaling, ERK phosphorylation, epithelial-cell proliferation, and inflammatory disease phenotypes. The reported findings support pathway involvement in the models described, while leaving the size, specificity, and clinical relevance of those effects unresolved.
How IGF-IR Inhibition Changes Cancer Cell Signaling
2026-11-15
NVP-AEW541 is documented as a selective IGF-IR kinase inhibitor with a reported IC50 of 0.086 μM. Its documented effects connect receptor autophosphorylation with altered cell-cycle behavior, apoptosis, proliferation, and context-dependent radiosensitization, while also illustrating why biochemical potency does not by itself predict cellular response.
How to Interpret ML-193 GPR55 Evidence
2026-11-14
ML-193 findings form a mechanistic chain from GPR55 antagonism and β-arrestin trafficking to neuronal calcium changes and pain-related behavior in rats. Each readout answers a different question, so the reported approximately 221 nM IC50 supports assay-specific antagonism rather than direct evidence of human analgesic efficacy.
Why CB1 Binding and Function Can Diverge
2026-11-13
Org 27569 illustrates how an allosteric ligand can increase agonist binding to CB1 while reducing receptor-mediated function. The apparent contradiction reflects different biological readouts: purified-receptor binding measures ligand cooperativity, whereas tissue contraction assays also depend on receptor conformation, signaling, and downstream physiology.
How 5-HT3 Blockade Relates to Antiemesis
2026-11-13
Granisetron HCl is identified as a 5-HT3 receptor antagonist with antiemetic activity. The useful scientific question is how an interaction at an ion channel can produce an organism-level reduction in emetic responses, and what evidence is needed to distinguish a plausible mechanism from product-specific efficacy.
Interpreting a 267 nM CXCL12 Binding Value
2026-11-12
A 267 nM binding value is a molecular interaction readout, not by itself a measure of anti-inflammatory efficacy. The documented description supports a focused interpretation of LIT-927 as a CXCL12-related ligand, while leaving the exact assay metric, functional direction, and biological model unresolved.
How Bile Acids Shape Cholestasis Readouts
2026-11-12
Ursocholic acid is described as a primary bile acid whose metabolism may connect bile composition with liver-cell survival, bile flow, inflammatory signaling, mitochondrial function, and bone-related effects in chronic cholestasis. The evidence supports a mechanistic interpretation, but not a quantitative estimate of efficacy for a specific material.
What Does Cy7 NHS Ester Fluorescence Measure?
2026-11-11
Cy7 NHS ester links primary-amine chemistry to near-infrared fluorescence. Its signal can report the presence and distribution of a covalently labeled molecule, but fluorescence location alone does not establish molecular targeting, biological activity, or therapeutic effect.